BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 28583379)

  • 21. Signaling protein signature predicts clinical outcome of non-small-cell lung cancer.
    Jin BF; Yang F; Ying XM; Gong L; Hu SF; Zhao Q; Liao YD; Chen KZ; Li T; Tai YH; Cao Y; Li X; Huang Y; Zhan XY; Qin XH; Wu J; Chen S; Guo SS; Zhang YC; Chen J; Shen DH; Sun KK; Chen L; Li WH; Li AL; Wang N; Xia Q; Wang J; Zhou T
    BMC Cancer; 2018 Mar; 18(1):259. PubMed ID: 29510676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.
    Chen H; Shen DP; Zhang ZZ; Liu JH; Shen YY; Ni XZ
    World J Gastroenterol; 2015 Feb; 21(6):1838-44. PubMed ID: 25684949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytoplasmic expression of maspin predicts unfavourable prognosis in patients with squamous cell carcinoma of the lung.
    Matsuoka Y; Takagi Y; Nosaka K; Sakabe T; Haruki T; Araki K; Taniguchi Y; Shiomi T; Nakamura H; Umekita Y
    Histopathology; 2016 Jul; 69(1):114-20. PubMed ID: 27297724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-141 is a biomarker for progression of squamous cell carcinoma and adenocarcinoma of the lung: clinical analysis of 125 patients.
    Zhang X; Li P; Rong M; He R; Hou X; Xie Y; Chen G
    Tohoku J Exp Med; 2015 Mar; 235(3):161-9. PubMed ID: 25746592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
    Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
    Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HSP90B1 overexpression predicts poor prognosis in NSCLC patients.
    Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X
    Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Prognostic Effect of MAC30 Expression on Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy.
    Ding H; Gui X; Lin X; Chen R; Ma T; Sheng Y; Cai H; Fen Y
    Technol Cancer Res Treat; 2017 Oct; 16(5):645-653. PubMed ID: 27688262
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.
    Tanuma J; Izumo T; Hirano M; Oyazato Y; Hori F; Umemura E; Shisa H; Hiai H; Kitano M
    Oncol Rep; 2010 Mar; 23(3):739-44. PubMed ID: 20127014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Main histologic types of non-small-cell lung cancer differ in expression of prognosis-related genes.
    Skrzypski M; Dziadziuszko R; Jassem E; Szymanowska-Narloch A; Gulida G; Rzepko R; Biernat W; Taron M; Jelitto-Górska M; Marjański T; Rzyman W; Rosell R; Jassem J
    Clin Lung Cancer; 2013 Nov; 14(6):666-673.e2. PubMed ID: 23870818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma.
    Stojsic J; Stankovic T; Stojkovic S; Milinkovic V; Dinic J; Milosevic Z; Milovanovic Z; Tanic N; Bankovic J
    Exp Mol Pathol; 2015 Feb; 98(1):27-32. PubMed ID: 25449334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Association of HAb18G with clinicopathologic features and prognosis in non-small cell carcinoma of lung].
    Xu XY; Zhi C; Li YM; Qi WJ; Mei JJ; Yan ZM; Shen H
    Zhonghua Bing Li Xue Za Zhi; 2012 Mar; 41(3):151-5. PubMed ID: 22800476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.
    Li Z; Zhang Y; Jin T; Men J; Lin Z; Qi P; Piao Y; Yan G
    BMC Cancer; 2015 Mar; 15():207. PubMed ID: 25880877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors.
    Göke F; Franzen A; Menon R; Goltz D; Kirsten R; Boehm D; Vogel W; Göke A; Scheble V; Ellinger J; Gerigk U; Fend F; Wagner P; Schroeck A; Perner S
    Chest; 2012 Oct; 142(4):1020-1026. PubMed ID: 22499828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.
    Qiu C; Dong W; Su B; Liu Q; Du J
    J Thorac Oncol; 2013 Apr; 8(4):429-35. PubMed ID: 23486264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KRAS genetic variant as a prognostic factor for recurrence in resectable non-small cell lung cancer.
    Sullivan I; Salazar J; Arqueros C; Andrés M; Sebio A; Majem M; Szafranska J; Martínez E; Páez D; López-Pousa A; Baiget M; Barnadas A
    Clin Transl Oncol; 2017 Jul; 19(7):884-890. PubMed ID: 28150169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts.
    Noro R; Ishigame T; Walsh N; Shiraishi K; Robles AI; Ryan BM; Schetter AJ; Bowman ED; Welsh JA; Seike M; Gemma A; Skaug V; Mollerup S; Haugen A; Yokota J; Kohno T; Harris CC
    J Thorac Oncol; 2017 Jan; 12(1):65-76. PubMed ID: 27613525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors.
    Cros J; Moati E; Raffenne J; Hentic O; Svrcek M; de Mestier L; Sbidian E; Guedj N; Bedossa P; Paradis V; Sauvanet A; Panis Y; Ruszniewski P; Couvelard A; Hammel P
    Neuroendocrinology; 2016; 103(5):495-9. PubMed ID: 26335532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of survivin expression in stage III non-small cell lung cancer patients treated with platinum-based therapy.
    Cho HJ; Kim HR; Park YS; Kim YH; Kim DK; Park SI
    Surg Oncol; 2015 Dec; 24(4):329-34. PubMed ID: 26690822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
    Go H; Jeon YK; Park HJ; Sung SW; Seo JW; Chung DH
    J Thorac Oncol; 2010 Mar; 5(3):305-13. PubMed ID: 20107422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.